IQVIA Holdings is the world's largest provider of biopharmaceutical development services and commercial outsourcing services. The company is the result of the 2016 merger of Quintiles Transnational, a contract research organization, and IMS Health, a healthcare data and analytics provider. IQVIA is headquartered in Research Triangle Park, North Carolina. The company provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and Asia-Pacific. It operates through two segments: Commercial Solutions and Research & Development Solutions. It also provides intelligent connections across all aspects of healthcare through its analytics, technology, big data resources, and extensive domain expertise. Its connected intelligence delivers actionable insights to enable customers to accelerate the clinical development and commercialization of new therapies. IQVIA has one of the largest databases of healthcare information in the world, which includes more than 1.2 billion comprehensive, longitudinal, non-identified patient records spanning sales and prescription data, medical claims, electronic medical records, genomics, and social media.

The major stock indices are all higher at midday on Friday, setting the stage for what appears to be a positive end to what has been a difficult week. Meanwhile, Bitcoin continues to enjoy a mini-Renaissance - up over 7% today and 23% over the past five days, but still down about 12% for the year to date. Over the course of the week, investors have been faced with ongoing earnings reports from major retailers, but attention has been hijacked at least to a degree by rising Treasury yields. And then there is the ongoing but arguably stalled conflict in the Middle East, where investors and the world at large are contemplating an apparent new phase that the White House is calling 'economic warfare.' What that will be and what impact it will have is an unknown. But as is always the case with unknowns, any form of uncertainty is not helpful in the eyes of Wall Street.

Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.

Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.